Megestrol Acetate is Used for treating anorexia, cachexia, or unexplained significant weight loss in AIDS patients. It was first introduced by Bristol Myers Squibb in its drug Megace on Approved Prior to Jan 1, 1982. Another drug containing Megestrol Acetate is Megace Es. 12 different companies have introduced drugs containing Megestrol Acetate.

Megestrol Acetate Patents

Given below is the list of patents protecting Megestrol Acetate, along with the drug name that holds that patent and the company name owning that drug.

Download patent list as spreadsheet

Get the complete list right in your inbox!

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Megace Es	US7101576	Nanoparticulate megestrol formulations	Apr 22, 2024 (Expired)	Endo Operations
Megace Es	US9040088	Nanoparticulate megestrol formulations	Apr 22, 2024 (Expired)	Endo Operations
Megace Es	US9101540	Nanoparticulate megestrol formulations	Apr 22, 2024 (Expired)	Endo Operations
Megace Es	US9101549	Nanoparticulate megestrol formulations	Apr 22, 2024 (Expired)	Endo Operations
Megace Es	US9107827	Nanoparticulate megestrol formulations	Apr 22, 2024 (Expired)	Endo Operations
Megace Es	US6592903	Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate	Sep 21, 2020 (Expired)	Endo Operations

Add above patents to watchlist

Megestrol Acetate's Family Patents

Full family tree

Megestrol Acetate Generic API Manufacturers

Several generic applications have been filed for Megestrol Acetate. The first generic version for Megestrol Acetate was by Usl Pharma Inc and was approved on Oct 2, 1987. And the latest generic version is by Chartwell Life Molecules Llc and was approved on Dec 1, 2017.

Given below is the list of companies who have filed for Megestrol Acetate generic, along with the locations of their manufacturing plants worldwide.